The short version of 冻干粉 fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-10-03. Anything still debated is marked as such rather than presented as settled.
Degradation pathways for tirzepatide include deamidation, oxidation, and aggregation, which are common for therapeutic peptides. These processes can be monitored by size-exclusion chromatography (SEC) for aggregates and ion-exchange chromatography for charge variants. Forced degradation studies under acidic, basic, oxidative, and thermal stress help identify potential impurities. The exact stability profile depends on formulation, concentration, and container-closure system.
Analytical characterization of tirzepatide typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) for purity assessment and peptide mapping. Mass spectrometry, often coupled with electrospray ionization, confirms molecular weight and sequence integrity. Amino acid analysis and capillary electrophoresis may also be used to detect impurities or degradation products. These methods are essential for batch release and stability studies.
Storage recommendations for tirzepatide generally specify refrigeration at 2–8 °C to maintain stability. The peptide should be protected from light and kept in its original packaging to prevent aggregation or adsorption. Freezing is not recommended because freeze-thaw cycles can cause aggregation or precipitation. Once dispensed, storage conditions and in-use periods follow product-specific labeling, which may allow room temperature storage for a limited time.
Like most synthetic peptides of this size, the material is commonly supplied as a lyophilised powder that appears white to off-white. It dissolves in aqueous buffers and in mixtures of water with a small proportion of organic solvent, though the fatty acid portion reduces solubility in pure water relative to short peptides. Hygroscopic behaviour is reported for many peptide powders, so weighing is usually performed quickly and under controlled humidity. Working solutions are typically prepared fresh and kept cold.
Long-term storage of lyophilised peptide powder is generally at minus twenty degrees Celsius or colder, with desiccant and protection from light. Short-term storage at two to eight degrees Celsius is common during active use. In solution, stability depends strongly on pH, concentration, and the presence of preservatives, and hydrolysis or aggregation can develop over weeks. Published stability data specific to this molecule are limited, so recommended conditions for research material are usually extrapolated from general peptide handling practice rather than from a dedicated study.
Bulk peptide material is normally characterised by reversed-phase high-performance liquid chromatography, which separates the target sequence from truncation products and other closely related impurities. Ultraviolet detection near 214 nanometres is common because the peptide backbone absorbs in that region. Mass spectrometry, usually electrospray ionisation coupled to a mass analyser, is used to confirm the molecular mass. Because the molecule carries a lipophilic side chain, gradient methods often need a relatively high organic modifier fraction to elute it within a practical retention window.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized or solid form |
| Solubility | Sparingly soluble in water | May require buffer or pH adjustment |
| Typical storage temperature | 2–8 °C | Refrigerated; protect from light |
| Common analytical method | RP-HPLC | For purity and impurity profiling |
| Molecular weight | Approximately 4813 Da | For the peptide backbone; varies with counterions |
As a peptide, tirzepatide is handled as a lyophilised solid in research settings and as a preserved solution in finished products. Aqueous solubility is pH dependent and reaches a minimum near the isoelectric point, which lies close to pH 5.4. Stock solutions are typically prepared in neutral or slightly basic buffer to limit precipitation. The solid is hygroscopic and should be equilibrated to room temperature before opening so that condensation does not form on the powder surface.
Recommended storage for reference material is a freezer at approximately -20 degrees Celsius, protected from light and moisture. Commercial injectable presentations are stored refrigerated between 2 and 8 degrees Celsius and must not be frozen. Product labelling generally permits a limited period at controlled room temperature once dispensed, with the exact window depending on the presentation. Repeated temperature cycling is avoided because it can promote aggregation or deamidation of the peptide chain.
Peptide active ingredients of this type are typically supplied as lyophilized powder because the dry form resists hydrolysis during transport. The material is hygroscopic, so vials are usually equilibrated to room temperature before opening to avoid condensation on the solid. Repeated freeze-thaw cycles can promote aggregation and are generally avoided by aliquoting stock into single-use portions. Personnel handling the powder work in controlled environments to limit inhalation of fine particles. Written procedures usually specify these steps rather than leaving them to individual judgment.
Long-term storage of the solid generally relies on temperatures at or below minus twenty degrees Celsius, while short-term working stocks may be held refrigerated. Light exposure is limited because photodegradation can alter side chains over extended periods. Solutions prepared for analysis are less stable than the dry powder and are typically used within the same working day. Buffer choice matters, since some aqueous conditions favor deamidation or oxidation at specific residues. Stability data are usually generated under defined accelerated conditions and then extrapolated with stated assumptions.
Identity and purity are established with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion verifies the primary sequence and detects substitutions. Size-exclusion chromatography quantifies aggregates and fragments, which are the impurities most often tracked for peptides of this size. Residual solvents, counterions, and water content fall under separate tests described in pharmacopeial chapters. Circular dichroism or nuclear magnetic resonance may be used in research settings to probe secondary structure, though such methods are less common in routine release testing.
固体状态的 tirzepatide 通常以冻干粉形式保存，推荐在低温、避光、干燥条件下存放，常见区间为 2 至 8 摄氏度，长期保存可考虑更低温度并避免反复冻融。冻融循环会导致肽链聚集或析出，从而影响后续定量结果。容器密封性与湿度控制同样是稳定性研究中反复强调的因素。
溶解操作一般使用注射用水或适宜的水性缓冲液，必要时加入少量助溶剂以改善溶解速度，但应避免剧烈涡旋振荡，因为剪切力可能促进聚集。配制后的溶液在冷藏条件下的稳定时间通常短于固体形态，具体时限取决于浓度、缓冲体系与容器材质。是否加入防腐成分，则取决于用途是否为多次取样。
Stability depends strongly on physical form. The dry powder is generally regarded as stable for extended periods when held at or below minus twenty degrees Celsius in a sealed, desiccated container. In solution, degradation pathways include deamidation of asparagine and glutamine residues, oxidation of methionine, and aggregation. Reaction rates for these pathways rise with temperature. Repeated freezing and thawing of solutions promotes aggregation, and light exposure can accelerate some oxidative changes. Buffer composition and pH influence which pathway dominates at a given temperature.
Regulatory and quality discussions place the peptide within established guidance for synthetic peptides and biologics. Forced degradation studies, in which samples are exposed to heat, acid, base, peroxide, and light, identify likely degradation products and validate the selectivity of analytical methods. Reference standards allow comparison across laboratories and production batches. Purity specifications reported in the literature usually combine chromatographic purity with mass confirmation. Which impurity thresholds are meaningful for long-term behavior is still debated, and no single universal specification has been adopted across all jurisdictions.
Turner also told Newshub programme The Project, that doing a "one-off emergency screening to get blood from someone who is unvaccinated" might create the impression that there is a potential problem, and urged people to "sit down and work through where their fears and anxieties", concluding that the New Zealand health services were offering the best quality service to the baby.
==== Other potential disadvantages ==== Processed foods may actually take less energy to digest than whole foods, according to a study published in "Food & Nutrition Research" in 2010, meaning more of their food energy content is retained within the body. Processed foods also tend to be more allergenic than whole foods, according to a June 2004 "Current Opinion in Allergy and Clinical Immunology" article. Although the preservatives and other food additives used in many processed foods are generally recognized as safe, a few may cause problems for some individuals, including sulfites, artificial sweeteners, artificial colors and flavors, sodium nitrate, BHA and BHT, olestra, caffeine and monosodium glutamate — a flavor enhancer.
=== Coupling with oxidative phosphorylation === According to the chemiosmotic coupling hypothesis, proposed by Nobel Prize in Chemistry winner Peter D. Mitchell, the electron transport chain and oxidative phosphorylation are coupled by a proton gradient across the inner mitochondrial membrane. The efflux of protons from the mitochondrial matrix creates an electrochemical gradient (proton gradient). This gradient is used by the FOF1 ATP-synthase complex to make ATP via oxidative phosphorylation. ATP-synthase is sometimes described as Complex V of the electron transport chain. The FO component acts as a channel that harnesses the proton flow to drive rotation. It is composed of a, b and c subunits. Protons in the inter-membrane space of mitochondria first enter the ATP-synthase complex through an a subunit channel. Then protons bind to the c subunits, which are oriented in a ring (the c-ring), where the number of c subunits determines how many protons are required to make the c-ring and the attached γ-rotor turn one full revolution. There are 8 c subunits in humans, thus 8 protons are required. Protons are released as a result of the rotation of the c-ring, being directed into the mitochondrial matrix along the a subunit channels. This proton reflux drives the mechanical rotation of the c-ring and the γ-axle. The rotation of the γ-rotor causes the sequential alternation of conformational states in the catalytic β-subunits in F1. There are three different conformational states, which are:
== Behavioral memory == As LTP is thought to underlie the processes of learning and memory, CaMKII is also crucial to memory formation. Behavioral studies involving genetically engineered mice have demonstrated the importance of CaMKII.
Sources: en.wikipedia.org
=== 29 July === Russian forces took the villages of Novoselivka Persha, 20 kilometers northwest of Avdiivka, and Vovche in Donetsk Oblast. The Russian defence ministry claimed to have intercepted 39 Ukrainian drones over five oblasts. Local media and officials claimed power failures along the western border due to damage caused by drone strikes. A fire occurred at an electrical substation in Tomarovka, Belgorod Oblast, and a power station in Glazunovka, Oryol Oblast was reported damaged, while falling debris damaged a “critical infrastructure facility” in Ostrogozhsky, Voronezh Oblast. Ukrainian authorities announced the arrest of six people in Odesa on suspicion of burning 15 military vehicles on behalf of Russia.
=== Biomaterials and Tissue Engineering === This program develops carriers for drug delivery and tissue regeneration scaffolds. Research combines polymer chemistry, stem cell differentiation, and 3D bioprinting to create vascular grafts, bone/cartilage replacements, and neural matrices. Studies explore relationships between material properties and biological responses.
=== Glucocorticoid activity === CPA is an agonist of the glucocorticoid receptor (GR), and has weak and partial glucocorticoid activity at high doses. In animals, CPA suppresses the secretion of adrenocorticotropic hormone (ACTH) from the pituitary gland, suppresses the production of corticosteroids like cortisol and corticosterone by the adrenal cortices, and decreases the weights of the adrenal glands and thymus. Conversely however, CPA shows no anti-inflammatory or eosinophilic effects in animals. As such, CPA, as well as related antiandrogens, show only some of the typical effects of glucocorticoids. CPA may produce mild glucucorticoid actions at high doses of more than 100 mg/day in humans. Clinically, the glucocorticoid effects of CPA appear to be relevant only at high doses in people with small body sizes (CPA exposure of more than 80 to 100 mg/m2), namely in the treatment of children with precocious puberty. No signs of secondary adrenal insufficiency have been observed with CPA. While various studies have clearly shown reduced cortisol and ACTH levels and ACTH responsiveness in humans with CPA therapy, some studies contradict these findings and report no such effects even with high doses of CPA. Due to negative feedback on the hypothalamic–pituitary-adrenal (HPA) axis, administration of exogenous glucocorticoids such as prednisone and dexamethasone suppress the secretion of adrenocorticotropic hormone (ACTH) from the pituitary gland and the production of cortisol from the adrenal glands.
Sources: en.wikipedia.org
RP-HPLC is widely used for purity and impurity profiling. Mass spectrometry confirms identity.
Typically refrigerated at 2–8 °C. Protect from light and avoid freezing.
Deamidation, oxidation, and aggregation products. SEC and ion-exchange chromatography are used.
It separates molecules by hydrophobicity, which is effective for distinguishing an intact peptide from truncated or chemically modified forms. A C18 column with an acidic water-organic mobile phase is a standard configuration.